triptans are a group of tryptamine-based drugs used to Rx acute migraines
they were introduced in the 1990's and have variable efficacy on aborting a migraine attack, and do not prevent it recurring.
they are not addictive and generally are effective within 30-90 minutes of responders.
poor responders should consider taking a dose within 20min of onset or trying a different triptan.
not for use in pregnancy
mechanism of action
act on serotonin 5-HT1B and 5-HT1D receptors in cranial blood vessels causing their vasoconstriction, and in nerve endings, and inhibition of pro-inflammatory neuropeptide release (eg. CGRP, substance P).
elderly > 65 yrs; pregnancy, lactation, children < 17 yrs
adverse effects
recurrence of migraine later that day
a range of common but usually not clinically important adverse effects
serotonin syndrome if concurrent use of other serotonergic agents or in overdose
large does of sumatriptan (> 200mg/d) may cause sulfhaemoglobinaemia
theoretically risk of:
coronary artery spasm but life-threatening cardiac events are rare, nevertheless, it should not be used in those with ischaemic heart disease
exacerbation of a migraine-induced neurologic event associated with intracranial vasoconstriction and CNS ischaemia
examples
sumatriptan
Imigran
usual oral dose is 50-100mg
usual s/c dose is 6mg
sumatriptan was the first triptan available and was introduced in the US in 1991
Zelrix was introduced in 2008 in the US as a computer chip controlled iontophoretic transdermal patch which can deliver a single dose through the skin within 30min.